By divesting its subsidiary in the US, Midatech Pharma PLC aims to simplify its R&D strategy and raise needed money to repay debt and progress its proprietary platforms to improve the delivery and quality of existing drugs. In particular it will focus on its lead product, which seeks to better Novartis AG's blockbuster Sandostatin LAR (octreotide acetate), according to the British biotech's recently installed CEO.
Based on recent clinical data Midatech – which was spun out of Cardiff University five years ago - has entered...
